Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Iovance Biotherapeutics (IOVA) Cost of Revenue (2023 - 2025)

Iovance Biotherapeutics has reported Cost of Revenue over the past 3 years, most recently at $43.1 million for Q4 2025.

  • Quarterly results put Cost of Revenue at $43.1 million for Q4 2025, up 14.08% from a year ago — trailing twelve months through Dec 2025 was $188.0 million (up 74.17% YoY), and the annual figure for FY2025 was $173.2 million, up 85.72%.
  • Cost of Revenue for Q4 2025 was $43.1 million at Iovance Biotherapeutics, up from $38.5 million in the prior quarter.
  • Over the last five years, Cost of Revenue for IOVA hit a ceiling of $56.7 million in Q2 2025 and a floor of -$5.4 million in Q4 2023.
  • Median Cost of Revenue over the past 3 years was $31.5 million (2024), compared with a mean of $27.0 million.
  • Biggest five-year swings in Cost of Revenue: soared 1430.15% in 2024 and later rose 14.08% in 2025.
  • Iovance Biotherapeutics' Cost of Revenue stood at -$5.4 million in 2023, then soared by 805.41% to $37.8 million in 2024, then grew by 14.08% to $43.1 million in 2025.
  • The last three reported values for Cost of Revenue were $43.1 million (Q4 2025), $38.5 million (Q3 2025), and $56.7 million (Q2 2025) per Business Quant data.